Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Time course of serum C-reactive protein levels during induction chemoradiotherapy and its correlation with treatment response and survival in patients with advanced esophageal squamous cell carcinoma.

Fujiwara H, Shiozaki A, Furutani A, Yoneda M, Kubota T, Komatsu S, Ichikawa D, Okamoto K, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Otsuji E.

Mol Clin Oncol. 2013 May;1(3):558-564. Epub 2013 Mar 5.

2.

[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy].

Yoneda M, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Shiozaki A, Komatsu S, Ichikawa D, Okamoto K, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Kokuba Y, Sonoyama T, Otsuji E.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2237-9. Japanese.

PMID:
21224533
3.

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.

Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T.

Oncol Rep. 2012 Aug;28(2):446-52. doi: 10.3892/or.2012.1847. Epub 2012 Jun 1.

4.

Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.

Yoneda M, Fujiwara H, Furutani A, Ikai A, Tada H, Shiozaki A, Komatsu S, Kubota T, Ichikawa D, Okamoto K, Konishi H, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Otsuji E.

Anticancer Res. 2013 Jun;33(6):2699-705.

PMID:
23749929
5.

Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A.

Clin Transl Oncol. 2006 Jan;8(1):22-30.

PMID:
16632436
6.

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Cancer. 2004 Oct 15;101(8):1776-85.

7.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
8.

Chemoradiotherapy with and without esophagectomy for advanced esophageal cancer.

Nakamura T, Ota M, Hayashi K, Eguchi R, Ide H, Takasaki K, Mitsuhashi N.

Hepatogastroenterology. 2006 Sep-Oct;53(71):705-9.

PMID:
17086873
9.

Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma.

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T.

J Surg Oncol. 2003 Aug;83(4):248-52.

PMID:
12884238
10.

Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.

Blanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin V, Hennequin C.

BMC Cancer. 2012 Mar 26;12:119. doi: 10.1186/1471-2407-12-119.

11.

Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.

Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.

Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.

PMID:
21968953
12.

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE.

Med Oncol. 2011 Dec;28 Suppl 1:S152-61. doi: 10.1007/s12032-010-9658-1. Epub 2010 Aug 21.

PMID:
20730572
13.

Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion.

Hamai Y, Hihara J, Emi M, Taomoto J, Aoki Y, Kishimoto I, Ibuki Y, Okada M.

Anticancer Res. 2013 Aug;33(8):3495-502.

PMID:
23898125
14.

The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.

Kato H, Fukuchi M, Manda R, Faried A, Takita J, Nakajima M, Miyazaki T, Sohda M, Fukai Y, Masuda N, Tsukada K, Kuwano H.

Anticancer Res. 2004 Nov-Dec;24(6):4091-6.

15.

Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.

Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Sasahara H, Shirouzu K, Suzuki G, Hayabuchi N, Inutsuka H.

J Surg Oncol. 2005 Jun 15;90(4):209-19.

PMID:
15906363
16.

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI.

Ann Oncol. 2004 Jun;15(6):947-54.

17.
18.

Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.

Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.

Ann Surg. 2013 Jul;258(1):66-76. doi: 10.1097/SLA.0b013e31828676c4.

PMID:
23470576
19.

C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.

Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M.

Anticancer Res. 2013 Nov;33(11):5065-74.

PMID:
24222151
20.

REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.

Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, Watanabe H, Maruyama K, Okuyama M, Ogawa J.

Ann Surg Oncol. 2006 Dec;13(12):1724-31. Epub 2006 Sep 30.

PMID:
17009160
Items per page

Supplemental Content

Write to the Help Desk